Conexeu Sciences Inc. Common Stock (CNXU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Conexeu Sciences Inc. Common Stock (CNXU) has a cash flow conversion efficiency ratio of -0.251x as of April 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.80 Million) by net assets ($7.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review CNXU financial flexibility index to assess the company's free cash flow relative to its total liabilities.
Conexeu Sciences Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Conexeu Sciences Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Conexeu Sciences Inc. Common Stock market capitalisation for the company's overall valuation and market capitalisation.
Conexeu Sciences Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Conexeu Sciences Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TBI Motion Technology Co Ltd
TW:4540
|
-0.091x |
|
AG Mortgage Investment Trust Inc
NYSE:MITT
|
0.037x |
|
GOCL Corporation Limited
NSE:GOCLCORP
|
-0.008x |
|
Circio Holding ASA
OL:CRNA
|
2.054x |
|
KYE Systems Corp
TW:2365
|
0.012x |
|
Caisse Régionale de Crédit Agricole du Morbihan
PA:CMO
|
0.004x |
|
SIGA Technologies Inc
NASDAQ:SIGA
|
0.000x |
|
OraSure Technologies Inc
NASDAQ:OSUR
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Conexeu Sciences Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Conexeu Sciences Inc. Common Stock from 2024 to 2025. View Conexeu Sciences Inc. Common Stock share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $7.35 Million | $-1.67 Million | -0.227x | +90.43% |
| 2024-10-31 | $94.96K | $-225.44K | -2.374x | -- |
About Conexeu Sciences Inc. Common Stock
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, b… Read more